The contribution of the sympathetic nervous system to the anabolic effect of estrogen on bone.
Completed
- Conditions
- osteoporosis1001329610005959
- Registration Number
- NL-OMON36023
- Lead Sponsor
- Academisch Medisch Centrum
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- Not specified
- Target Recruitment
- 32
Inclusion Criteria
female sex
last menstrual cycle 12-60 months ago
Exclusion Criteria
Contraindications to HRT, beta-agonist or beta-antagonist treatment, such as cardiovascular disease, astma, COPD, renal or hepatic insufficiency
Any medication or disease influencing bone turnover
Prior VTE or breast cancer
Current osteoporosis defined by a DXA Z-score >-2.5
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method <p>The main study parameter is the difference in change of serum concentrations of<br /><br>bone turnover markers (procollagen type I N propeptide (P1NP) and C-terminal<br /><br>crosslinking telopeptides of collagen type I (CTX)) compared in the treatment<br /><br>and control groups(4).</p><br>
- Secondary Outcome Measures
Name Time Method <p>A secondary parameter is the change in number of circulating stem cells and<br /><br>osteogenic cells(7).</p><br>